Organizations Filed Purposes:
THE MISSION OF THE LIEBER INSTITUTE IS TO TRANSLATE THE UNDERSTANDING OF BASIC GENETIC AND MOLECULAR MECHANISMS OF SCHIZOPHRENIA AND RELATED DEVELOPMENTAL BRAIN DISORDERS INTO CLINICAL ADVANCES THAT CHANGE THE LIVES OF AFFECTED INDIVIDUALS.
CLINICAL SCIENCES: THE CLINICAL SCIENCE DIVISION INVESTIGATES MECHANISMS OF SCHIZOPHRENIA AND RELATED BRAIN DISORDERS IN CLINICAL STUDIES AND IN BIOLOGICAL MATERIAL FROM CLINICAL SAMPLES SPECIFICALLY ASCERTAINED, EVALUATED AND MANAGED BY LIBERER INSTITUTE STAFF AND THROUGH COLLABORATIONS WITH JOHNS HOPKINS UNIVERSITY, THE NATIONAL INSTITUTE OF MENTAL HEALTH (NIMH), UNIVERSITY OF BARI (ITALY), AND OTHERS.
BASIC SCIENCES: THE CREATION OF MODEL SYSTEMS AT THE LIEBER INSTITUTE TO STUDY PSYCHIATRIC ILLNESS IS THE MAJOR GOAL OF THE BASIC SCIENCES RESEARCH PROGRAM. USING OUR UNIQUE COLLECTION OF HUMAN BRAIN MATERIAL AND INDUCED PLURIPOTENT STEM CELL LINES, WE ARE DEFINING THE MOLECULAR SIGNATURE OF DISEASE RISK. TO PROVIDE THE BASIS FOR THERAPEUTIC INTERVENTION WE ARE DEVELOPING NEW TECHNOLOGIES USING HUMAN STEM CELLS TO IDENTIFY THE FUNCTIONAL CONSEQUENCES OF GENETIC RISK FACTORS.
DRUG DISCOVERY: IMPROVED GENETIC UNDERSTANDING OF DISEASES OF BRAIN DEVELOPMENT IS REVEALING NEW DRUG DISCOVERY OPPORTUNITIES. GUIDED BY GENETICS, THE LIEBER INSTITUTE DRUG DISCOVERY DIVISION IS INVESTIGATING NEW TARGETS FOR PSYCHIATRIC DISEASES, WITH THE GOAL OF VALIDATING INNOVATIVE APPROACHES THAT WILL LEAD TO NOVEL MEDICINES FOR PATIENTS SUFFERING FROM PSYCHIATRIC DISEASE. THE DRUG DISCOVERY DIVISION MAINTAINS A STATE OF THE ART MEDICINAL CHEMISTRY LABORATORY AND UNIQUE CAPABILITIES IN TARGET VALIDATION.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Daniel R Weinberger | CEO & DIRECTOR | 40 | $681,654 |
| Thomas Michael Hyde | CHIEF MEDICAL OFFICER | 40 | $399,073 |
| Elaine Jones | CHIEF OPERATING OFFICER | 40 | $388,882 |
| Joel E Kleinman | ASSOC. DIR. OF CLINICAL SC | 40 | $387,629 |
| Andrew Maslan | CFO & TREASURER | 40 | $387,075 |
| Kari L Stoever | CHIEF EXT. RELATIONS OFFIC | 40 | $286,934 |
| James Barrow | ASSOC. DIR. OF DRUG DISCOV | 40 | $247,385 |
| Andrew Jaffe | LEAD INVESTIGATOR | 40 | $222,352 |
| Richard Straub | SR. RESEARCH ASSISTANT | 40 | $187,714 |
| Brady Maher | LEAD INVESTIGATOR | 40 | $186,038 |
| Venkata Satyanand Mattay | FORMER ASSOC. DIR. OF NEUROIMAGIN | 22 | $168,275 |
| Ronald Mckay | FORMER DIRECTOR OF BASIC SCIENCES | 10 | $113,846 |
| Robert Muse | DIRECTOR | 1 | $0 |
| Paul B Rothman Md | DIRECTOR | 1 | $0 |
| Milton Maltz | DIRECTOR | 1 | $0 |
| Tamar Maltz | DIRECTOR | 1 | $0 |
| Mary Rubin | DIRECTOR | 1 | $0 |
| Stephen Lieber | DIRECTOR | 1 | $0 |
| Steven S Sharfstein Md | DIRECTOR | 1 | $0 |
| Herbert Pardes Md | CHAIRMAN OF THE BOARD | 1 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/202101209349300235_public.xml